{name}
{subtitle}
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat and Rituximab for Patients With Relapsed/Refractory Follicular Lymphoma
city
~10 mi. (Weslaco, Texas, +19 more cities)
facility
USOR/Texas Oncology
drug
rituximab, +1 more drug
drug type
immunotherapy, +1 more type
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
city
~25 mi. (Harlingen, Texas, +126 more cities)
facility
Valley Cancer Associates PC
drug
nivolumab, +2 more drugs
drug type
chemotherapy, +1 more type
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
city
~25 mi. (Harlingen, Texas, +29 more cities)
facility
Valley Cancer Associates PA
drug
avelumab, +4 more drugs
drug type
chemotherapy, +2 more types
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
city
~27 mi. (McAllen, Texas, +160 more cities)
facility
USOR: Texas Oncology - McAllen South Second
condition
Fallopian Tube Carcinoma, +2 more conditions
drug type
chemotherapy, +1 more type
Study of Sacituzumab Govitecan-hziy (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-programmed Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Immunotherapy
city
~27 mi. (McAllen, Texas, +17 more cities)
facility
Texas Oncology Cancer Care and Research Center
drug type
chemotherapy, +1 more type